Ads
related to: dacogen treatment for aml patients- AML Information
Read More Information About
mIDH1 & Acute Myeloid Leukemia.
- Dosing & Management
Learn About Dosing For R/R mIDH1
Acute Myeloid Leukemia.
- FAQ Page
Additional Questions? Visit Our FAQ
Page For More Information.
- Connect with a Rep
Schedule an Appointment with
A Representative Today
- Test To Target mIDH1
Learn How To Test To Target IDH1
Mutations In Your Patients With AML
- Access & Resources
HCPs - More Information & Resources
Are Available For You Here.
- AML Information
Search results
Results From The WOW.Com Content Network
Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. [4] It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). [5] Chemically, it is a cytidine ...
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
Decitabine/cedazuridine is indicated for treatment of adults with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary myelodysplastic syndromes with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1 ...
Azacitidine is indicated for the treatment of myelodysplastic syndrome, [4] for which it received approval by the U.S. Food and Drug Administration (FDA) on 19 May 2004. [11] [4] [12] In two randomized controlled trials comparing azacitidine to supportive treatment, 16% of subjects with myelodysplastic syndrome who were randomized to receive azacitidine had a complete or partial normalization ...
The drug has concluded phase I clinical trials for acute myeloid leukemia. [5] Interim results were presented in Dec 2014. [6] and published April 2015.[7]Based on interim data from ongoing phase I clinical trials presented at the 57th Annual Meeting of the American Society of Hematology (ASH), researchers at Seattle Genetics have planned a phase III clinical trial to begin in 2016.
A hypomethylating agent (or demethylating agent [1]) is a drug that inhibits DNA methylation: the modification of DNA nucleotides by addition of a methyl group.Because DNA methylation affects cellular function through successive generations of cells without changing the underlying DNA sequence, treatment with a hypomethylating agent is considered a type of epigenetic therapy.
Ads
related to: dacogen treatment for aml patients